Sagent Pharmaceuticals - Top 20 VC deals of 2007

Company: Sagent Pharmaceuticals
Based: Schaumburg, IL
Amount: $53M
Round: First
Investors: Capricorn Management, Vivo Ventures

Scoop: Sagent Pharmaceuticals brings finished pharmaceutical therapies onto the U.S. market; it is focused on injectable products. The company currently has more than 200 products in development, with more than 30 submissions to the FDA expected by the end of 2007. Sagent expects to double its FDA submissions in 2008.

More News:
Start-ups snare big rounds of venture funds. Report

Sagent Pharmaceuticals - Top 20 VC deals of 2007

Suggested Articles

Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new CMO.

Aldeyra Therapeutics aced a phase 3 trial of reproxalap for allergic conjunctivitis, sending its stock up at least 66% in premarket trading.

The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA.